Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs

 Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice
                          President, Medical Affairs

PR Newswire

NEW YORK, March 13, 2013

NEW YORK, March 13, 2013 /PRNewswire/ --Keryx Biopharmaceuticals, Inc.
(NASDAQ: KERX), a biopharmaceutical company focused on the acquisition,
development and commercialization of medically important pharmaceutical
products for the treatment of renal disease (the "Company"), today announced
the appointment of Amit Sharma, M.D. to the newly created position of Vice
President, Medical Affairs.

Amit Sharma, M.D., is an accomplished board certified nephrologist, internist,
and hypertension specialist who has a broad-based background in chronic kidney
disease and dialysis.Recently, Dr. Sharma was 
Medical Director, Medical
Affairs, at Reata Pharmaceuticals. From 2005-2012, Dr. Sharma served as a
Medical Director and Senior Advisor for Liberty Dialysis, LLC, a medium-size
dialysis organization with over 300 dialysis clinics. Liberty was sold 
in
2011 to Fresenius Medical Care AG for $1.7 billion. From 2001 to 2005, Dr.
Sharma served as the Director of the Dialysis Unit and of the Chronic Kidney
Disease Clinic for the Naval Medical Center, San Diego.

Dr. Sharma received his medical degree from 
Louisiana State University
Medical Center-New Orleans. He completed his 
fellowship in Nephrology and
Hypertension from University of California in San Diego in 2001. Dr. Sharma
also has extensive experience conducting
 primary research and as a principal
investigator for numerous clinical trials in the field of nephrology and
hypertension. He has published in many respected peer reviewed journals and he
is a well known presenter for national and international meetings.

Ron Bentsur, the Company's Chief Executive Officer, commented, "We are
thrilled to welcome Dr. Sharma to Keryx. Dr. Sharma has a prominent national
reputation and a proven track record of success within the dialysis
community. I believe that Dr. Sharma's vast knowledge and experience of
dialysis care will be particularly invaluable to the Company as we continue to
expand our presence in this field."

Dr. Sharma stated, "I am excited to be joining Keryx. I view Zerenex to be a
uniquely attractive compound that can potentially alter current practice
patterns with the ultimate aim of improving the lives of dialysis and chronic
kidney disease patients worldwide. I look forward to applying my nephrology
and dialysis expertise to contribute towards the success of Zerenex."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3
clinical program for Zerenex for the treatment of hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease, conducted pursuant
to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx
expects to submit a New Drug Application with the FDA in the second quarter of
2013 and a Marketing Authorization Application with the EMA in mid-2013.
Zerenex is also in Phase 2 development in the U.S. for the management of
phosphorus and iron deficiency in anemic patients with Stages 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its
New Drug Application for marketing approval of ferric citrate in Japan for the
treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx
is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.
The factors that could cause our actual results to differ materially are
identified from time to time in our reports filed with the Securities and
Exchange Commission. Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release and prior
releases are available at http://www.keryx.com. The information in our website
is not incorporated by reference into this press release and is included as an
inactive textual reference only.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://www.keryx.com